Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02210832 · ClinicalTrials.gov registry record · NA
Financial Incentives for Smoking Cessation Among Disadvantaged Pregnant Women
A NA study, sponsored by University of Vermont.
- Completed
- Registry status
- NA
- Development phase
- 257
- Enrollment target
NCT02210832: Completed NA study, sponsored by University of Vermont.
NCT02210832 is a NA study that has completed, run by University of Vermont. The registered enrollment target is 257 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02210832, a NA study, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- NA
- Development phase
- 257 participants
- Enrollment target
Study Summary
Investigators will examine whether adding financial incentives to current best practices for smoking cessation during pregnancy (i.e., referral to pregnancy-specific counseling using a telephone quit line) increases cessation rates and improves infant health. While more expensive upfront compared to best practices alone, the investigators hypothesize that this treatment approach will be economically justified by the later cost savings associated with more women quitting, having healthier babies, and needing less healthcare. It should also help to reduce the greater risk for health problems often seen among those who less well off economically.
Primary Outcome
Abstinence was defined as woman reports that she has not smoked, not even a puff, in the past 7 days and self-report is biochemically verified via urine cotinine testing
Interventions
- BEHAVIORAL Best practices
- BEHAVIORAL financial incentives
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 257 participants |
| Start Date | 2014-01-31 |
| Est. Completion | 2020-01-31 |
| Phase | NA |
What the finished NCT02210832 record still lists
NCT02210832 is an interventional study that assigns participants to a tested intervention. The registered 257 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 2 interventions - of which Best practices is the first listed.
NCT02210832 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02210832 about?
NCT02210832 is a clinical study titled "Financial Incentives for Smoking Cessation Among Disadvantaged Pregnant Women". Investigators will examine whether adding financial incentives to current best practices for smoking cessation during pregnancy (i.e., referral to pregnancy-specific counseling using a telephone quit line) increases cessation rates and improves infant health. While more expensive upfront compared to...
What is the current status of trial NCT02210832?
This trial is currently completed. It is a NA study. The enrollment target is 257 participants. The study started on 2014-01-31. Estimated completion is 2020-01-31.
What interventions are being tested in trial NCT02210832?
The interventions under investigation include: Best practices (BEHAVIORAL), financial incentives (BEHAVIORAL).
Who is sponsoring clinical trial NCT02210832?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02210832's enrollment target sits among peer trials
257 403rd of 2000 higher than 1,597 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03618550 · 257 participants · Phase 2
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
- NCT04674267 · 257 participants · NA
Resilience and Equity in Aging, Cancer, and Health (REACH)
- NCT06099288 · 257 participants · NA
Strong Families Start at Home/Familias Fuertes Comienzan en Casa
- NCT06207084 · 257 participants · NA
The Fit With Us Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI